Case study of the anemic patient: epoetin alfa--focus on CQI and patient management.

Epoetin alfa, widely used in treating the anemia caused by end-stage renal disease, provides several benefits to patients, including increased energy and an improved sense of well-being. Achieving these benefits depends on appropriate patient management. This article discusses how a multidisciplinary renal team can use continuous quality improvement principles to manage a suboptimal response to Epoetin alfa therapy caused by aluminum toxicity.